Treatment Resistant Major Depressive Disorder Clinical Trial
Official title:
STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment resistant MDD. Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments and a prospective inadequate response to treatment with bupropion during the open-label, lead-in period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05323019 -
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
|
Phase 2 | |
| Completed |
NCT02977299 -
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
|
Phase 4 | |
| Terminated |
NCT03254017 -
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial
|
N/A | |
| Withdrawn |
NCT05438758 -
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
|
Phase 2 | |
| Active, not recruiting |
NCT01798407 -
DBS of the Lateral Habenula in Treatment-Resistant Depression
|
N/A | |
| Completed |
NCT00986479 -
This is a Study to Determine the Antidepressant Effects of AZD6765
|
Phase 2 |